LONDON, April 30 /PRNewswire/ --

LONDON, April 30 /PRNewswire/ --

Following the embargoed news released by the Queen Mary University of London concerning the oral MS drug cladribine and the results due to be presented at the American Academy of Neurology meeting, please find below a statement from the MS Society.

Dr Lee Dunster, Head of Research at the MS Society, said: These are remarkable results and being able to take a tablet instead of having injections will be a huge step forward for people with MS.

The evidence is there, but we now need to see cladribine move smoothly through the regulatory process and the price the manufacturer sets will play a crucial part in that.

This week is MS Week. For more info, go to http://www.msweek.org.uk

ANDOVER, England, April 30 /PRNewswire/ --

Almost 1 in 8 managers in the UK has a problem trusting their staff when it comes to taking time off to visit the dentist, research released today reveals.

According to Simplyhealth's Annual Dental Survey, 13% of bosses dictate when employees can visit the dentist and in some cases, actively discourage any visits to the dentist during working hours.

But while many managers admit to subjecting their staff to high levels of scrutiny, the impact of employees not being given time to attend to dental matters threatens to have an adverse effect on their career.

At least once a year, Cosmo’s cover story is about how to have better, longer sex: a turgid treatise on positions and anatomy.  Our finest ladies’ mags are ignoring the obvious.

To improve the mating of our species, we must learn from the mistakes of garden spiders and band together to end sexual cannibalism once and for all.  

Female Argiope spiders only want what all of us want—the upper hand in the war of the sexes.  But your friendly neighborhood garden spider has more at stake than the proper replacement of the toilet seat. 

COMMACK, New York, April 29 /PRNewswire/ --

It is with great privilege that Avery Biomedical Devices, Inc. (ABD) announces the appointment of Abbott Krieger, M.D., F.A.C.S. as Chief Clinical Liaison.

Have we really stopped evolving? In Cosmos magazine, Steve Jones argues that human evolution is coming to an end:

The question I have is: will human evolution really continue? I think the evidence shows that human evolution has largely come to a halt.

He lists three components necessary for human evolution:

First of all there's variation, which comes from mutation. Second, natural selection, which comes from inherited differences between individuals and their ability to reproduce.

ROCHESTER, New York, April 29 /PRNewswire/ --

- Land and Special Operations Forces Will Acquire Harris Multiband and HF Technology to Enable Communications Interoperability for U.S., NATO and Coalition Operations

Harris Corporation (NYSE: HRS), an international communications and information technology company, has been awarded a contract totaling US$20 million from the Polish Ministry of National Defense (MoND) to deliver a combination of multiband and HF tactical radios for Poland's Land and Special Operations Command Forces.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090429/FL07552 )

When a fake pandemic is being generated by media corporations having a slow news week, fake medicine is sure to pop up and take advantage of it.   The Royal Pharmaceutical Society of Great Britain (RPSGB) today issued a warning to the public about the risks of buying online medicines for swine influenza, such as Tamiflu or Relenza.

David Pruce, RPSGB Director of Policy said, "With the current fears about swine flu, we are concerned that unscrupulous people are exploiting the public's fears about swine flu by offering to sell the antiviral drugs Tamiflu and Relenza over the internet.

"This is a golden opportunity for counterfeiters to offer fake supplies of these drugs.

DUSSELDORF, Germany, April 29 /PRNewswire/ --

- Strong Focus on the Markets of Pharma Life Science

- Annual General Meeting Passes Dividend of EUR0.40 per Share

The Annual General Meeting of Gerresheimer AG today passed an unchanged dividend of EUR0.40 per share following the record year in 2008.

The Company finished the financial year 2008 with record results. Gerresheimer achieved sales of EUR1.06 billion (prior year EUR957.7m) and operating results (adjusted EBITDA) of EUR206.4m (prior year EUR181.6m).